

Adjusting to IDMP

Access needs and business challenges of drug database providers

jean-francois.forget@vidal.fr

VIDAL Group?



- European Drug Information company headquartered in Paris, France
- Providing reference Drug Information Systems (DIS) in over 20 countries (EMEA / LatAm)
- Over **200 staff** across Europe (France, Germany, Spain):
 - Scientific team (pharmacists, physicians...)
 - Technical team (medical informatics & software engineers, architects...)
- Partnerships with over 150 integrators (EHR, Health IT...)

Significant Events in the DIS Landscape


- Development and maturity of the internet -> increasingly distributed collaboration and open-data
- Development and maturity of open-source software and open-source data → increased technology support
- Establishment of standards at different layers of the "interoperability" stack → increased interoperability
 - Semantic Web standards (W3C standards)
 - HL7
 - ISO IDMP, SNOMED, LOINC,
 - ISO/TS 19256 'Medicinal Product Dictionary': the link between IDMP and clinical health care
- → This creates opportunities for drug databases to focus on core business: contribute to proper use of health products on the point of care = drug information contextualisation, DSMs, and analytics

From trusted sources of information to end users: Each skill "layer" creates added value

EHR Heart or designal works of the state of the & digital **API & Database** production (IT) **Data Compilation, synthesis** Formatting & Structuring (Physicians, pharmacist) Ministry of health, Drug agencies, Scientific Societies, experts Official drug formularies (list of drugs), SPCs, Guidelines, Pubmed

Integration in the HIS workflow thru APIs (Soap, Rest...), or digital products (mobile, web...)





VIDAL content usages



		Treatment procedure	Check	Inform	Administer	Substitute	Bill and Supply
Monographs	Absolues: • Allergie aux antibiotiques de la famille des bêta-lactamines (pénicillines et céphalosporines) ou à l'un des autres constituants. • Phényloétonurie, en raison de la présence d'aspartam (comprimé dispersible et poudre pour suspension buvable). Relatives: • Méthotrexate : d' Interactions.		X	X	X	X	
Protocols	Bronchiolite Bronchite ou trachéo- bronchite Pas d'antibiotique (Sauf cas particuliers) Antibiothérapie probabiliste Antibiothérapie probabiliste Hospitalisation	X		X		X	
Economic	Codes CIP Liste Base remb. Taux remb. Labo exploitant 3417172 3400934171727 I 4.18 65% GlaxoSmithKline 3319819 3400933198190 I 1.19 65% GlaxoSmithKline 3305496 3400933054960 I 1.84 65% GlaxoSmithKline			X		X	X
CDS	© Clinical Decision Support		X			X	






- Standard terminologies have been integrated at both the disease level (ICD10, ICD9, ICPC...) and the drug level (when available: INN*, ATC, EDQM standard terms, UCUM...)
- So far, Vidal has adapted the dm+d VMP** model as a backbone for pharmaceutical products
- Medicinal products local ID are used when available but more normalisation at this level will be a great step forward as global standards become available ...

The model supports both global / national and Grot document, structured information & DSMs





Local Documentation SPCs, Leaflet

> Medico economics **Data and DSMs**

> > Strength,

unit of measure Breakabiliry Price / Reimb

SPC based Therapeutics DSMs

EBM Documentation

Therapeutics DSMs

Drug-drug Drug-Health Overdosage Side effects ... e.g. Usages

Prescription Dispensation Administration Medico economic tools **DRG** tools


Prescription

interoperability Cross border

Analytics



EHR integration use cases: multilingual DSMs based on global.... and local data



Discussion / conclusion



- Mapping with local formularies (PhP<->MP<->packaging) is the "cornerstone" for usability in health informatics
- IDMP and article 57 database is a huge opportunity to fix it at a global level
- The major question for us is: will a unique set of MpID and PhPID be published as a global repository for all healthcare providers... and when?
- If the answer is yes, in the short/middle term, strong communication could motivate the market to be prepared to adopt one global repository in some years....and not promote new local or specific solutions



Thank you...

jean-francois.forget@vidal.fr